FARALLON CAPITAL MANAGEMENT, L.L.C.FARALLON CAPITAL MANAGEMENT, L.L.C.

Institutional investor · Portfolio as of Q3 2022

SEC EDGAR SourceSEC Filings

Top Holdings311 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction
SPYSPY
PUT

STATE STREET SPDR S&P 500 ETF TRUST CL USD INC

4.7M$1.7B9.1%
Increased

IQVIA HOLDINGS INC

3.2M$581M3.2%$145.73+24.62%
16 qtrssince 2018-Q4
Decreased
0

THERMO FISHER SCIENTIFIC INC

1.1M$569.1M3.1%$395.98+29.24%
12 qtrssince 2019-Q4
Decreased
0
CHNGCHNGDelisted

CHANGE HEALTHCARE INC

18.1M$496.9M2.7%
7 qtrssince 2021-Q1
Increased
82

ARAMARK

15.9M$496.8M2.7%$24.89-12.36%
8 qtrssince 2020-Q4
Decreased
0

BOSTON SCIENTIFIC CORP

12.2M$470.6M2.6%$38.48+2.24%
9 qtrssince 2020-Q3
Decreased
0

TRANSUNION

7.9M$470.4M2.6%$90.56-35.32%
16 qtrssince 2018-Q4
Increased
57

CLARIVATE PLC

40.5M$380.7M2.1%$12.74-27.88%
3 qtrssince 2022-Q1
Increased
78

ANTHEM INC

801,400$364M2.0%$291.80+49.24%
16 qtrssince 2018-Q4
Decreased
0
TWTRTWTRDelisted

TWITTER INC

7.8M$340M1.9%
2 qtrssince 2022-Q2
Increased
52

MICROSOFT CORP

1.4M$335.2M1.8%$147.45+56.87%
16 qtrssince 2018-Q4
Increased
55

CENTENE CORP

4.3M$330.9M1.8%$59.51+30.53%
11 qtrssince 2020-Q1
Decreased
0

ALPHABET INC-CL C

3.4M$324.1M1.8%$96.77+0.61%
16 qtrssince 2018-Q4
Increased
79
ATVIATVIDelisted

ACTIVISION BLIZZARD INC

4.2M$309.7M1.7%
3 qtrssince 2022-Q1
Increased
52
AZNAZN
ADR

ASTRAZENECA PLC

5.6M$306.3M1.7%$114.06-10.36%
5 qtrssince 2021-Q3
Increased
58

EQUIFAX INC

1.8M$306M1.7%$192.36-15.13%
16 qtrssince 2018-Q4
Increased
54

HOWMET AEROSPACE INC

9.8M$304.4M1.7%$28.78+6.16%
10 qtrssince 2020-Q2
Decreased
0

MASTERCARD INC - A

1.1M$303.8M1.7%$346.49-18.93%
7 qtrssince 2021-Q1
Decreased
0

SALESFORCE.COM INC

2.1M$296.4M1.6%$194.26-25.33%
12 qtrssince 2019-Q4
Increased
57
ZENZENDelisted

ZENDESK INC

3.9M$296M1.6%
4 qtrssince 2021-Q4
Increased
79
$18.2B
AUM
311
Positions
Q3 2022
Filing
Rating · 1.0
Quarterly Portfolio Change
+22%Q2'21$24.5B-13%Q3'21$21.4B-7%Q4'21$20B+3%Q1'22$20.7B-11%Q2'22$18.4B-1%Q3'22$18.2B
Activity profile
$ moved · Q3'22
New16%Increased39%Decreased30%Exited15%
Composition
Equity vs derivatives
Equity90%Puts10%Calls0%
Holding period
Avg 1.3 years
<1Q4%1-4Q28%1-2Y50%2Y+18%

FARALLON CAPITAL MANAGEMENT, L.L.C. manages $18.2B across 311 positions as of Q3 2022. Top holdings: SPY (9.1%), IQV (3.2%), TMO (3.1%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 1/5.0.

Q3 2022 Summary

Active quarter - 18 new positions, 23 exits, 41 increased. Top move: CHNG (INCREASED, conviction 82). Portfolio: $18.2B across 311 positions.

Top holdings by portfolio weight

Total AUM$16B
IQV3.19%
TMO3.13%
CHNG2.73%
ARMK2.73%
BSX2.58%
TRU2.58%
CLVT2.09%
ELV2.00%
TWTR1.87%
MSFT1.84%
Other1.82%

Portfolio allocation by GICS sector

Sectors11
Healthcare31.52%
Unknown21.76%
Technology14.62%
Financial Services12.19%
Industrials9.40%
Communication Services5.37%
Real Estate2.55%
Basic Materials1.73%
Utilities0.53%
Consumer Cyclical0.25%
Other0.07%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown, Technology
Compare DNA across all funds
7-dimension quality assessment
Weak(1.0 / 5.0)
Track RecordNo data
Conviction43
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
8Q
CRNXCRNXCRINETICS PHARMACEUTICALS IN
Q3 2024 Q2 2026+8.5M shares+$314.1M
7Q
BBIOBBIOBRIDGEBIO PHARMA INC
Q4 2024 Q2 2026+9M shares+$755.7M
5Q
BSXBSXBOSTON SCIENTIFIC CORP
Q2 2025 Q2 2026+6.8M shares+$69.5M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used